TickerTalks
Browse all tickers →
TickerTalks›$RNA
RNRNA

Atrium Therapeutics, Inc.

$RNA·$153M·Biotechnology·Healthcare
$8.28+1.0%1Y-44.5%
Price updated 10m ago·X counts updated 11d ago
RNRNA
$RNAAtrium Therapeutics, Inc.
$8.28+1.04%69 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $RNA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

69X posts · last 7 days
Sep 7Sep 14
Mixed sentimentAI analysisGenerated by AI from underlying data21 posts analyzed · as of 2026-09-15

There's a real confusion on the ticker — the current 'new RNA' (post-Avidity-sale to Novartis) sits below cash at $263.9M with runway to mid-2028 and just earned a $15M BMY milestone. But the tape got hit ~23% on the Novartis del-desiran DM1 Phase 3 fail, even though the ticker no longer holds that asset. The takeaway from longs: valid RNA franchise is disconnected from the noise; commercial-asset value went up post-fail.

Read what X is saying about $RNA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $RNA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Comeback attemptWinding up for a moveAI verdict · as of 2026-09-24

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

The new RNA (post-Avidity Novartis sale) got hit 23% on the Novartis del-desiran DM1 fail — but Atrium no longer owns that asset.

Atrium Therapeutics is the residual business left after Novartis acquired Avidity Biosciences' del-desiran DM1 asset — the ticker $RNA carried over but the assets changed. Trading below cash at $263.9M market cap with runway to mid-2028, plus a fresh $15M BMY milestone.

  • The setup is unusual: the market hit RNA -23% on Novartis's DM1 Phase 3 failure — but del-desiran was sold to Novartis, so Atrium doesn't own it anymore. The sell-off reflects ticker confusion, not asset exposure to the failure.
  • The financials reflect the pre-launch clinical-stage biotech reality: -410% operating margin on modest revenue, but sitting below cash means there's a specific asset-value floor. The BMY milestone is the type of pipeline-monetization event that de-risks burn.
  • Structural setup is broken: 30% below the 50-day, 9-11% pre-market fall. This is a name where longs are trying to arbitrage the disconnect between ticker damage and actual asset ownership, which takes time to normalize.

November 12 earnings — specific pipeline update and any BMY milestone details are what break the coil upward; another ticker-confusion sell-off or a specific pipeline miss continues the drift.

Agrees with X sentimentAgree with the honest confusion-read — the $RNA ticker post-Avidity-sale is genuinely disconnected from the Novartis del-desiran DM1 Phase 3 failure, and the longs' framing that commercial-asset value went up post-Avidity-fail is directionally right (Avidity got acquired for its assets, then those assets failed at the acquirer, but Atrium doesn't own them).

What to watch: November 12 earnings — pipeline update, BMY milestone details; specific pipeline progress or milestone details break the coil, another ticker-confusion sell-off continues the drift.

On the calendar: 2026-11-12 — Q3 earnings

Read the AI verdict on $RNA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Biotech delivering RNA therapeutics directly to cardiac muscle to treat genetic cardiomyopathies with unmet medical need.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RNA.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver; MRNA's personalized cancer vaccine (melanoma Phase 3 Oct readout) has extended a 137% monthly run. IBB +42% T12M reflects broad RNA-medicine and gene-editing multiple re-rating; GLP-1 pipeline names (ALT, VKTX, KLRA) are the secondary near-term catalyst cohort.

What this means for $RNA

Direct beneficiary — Atrium Therapeutics develops RNA-based medicines; as the RNA-medicine sector re-rates on MRNA's cancer vaccine momentum, early-stage RNA platform companies receive sentiment-driven multiple expansion alongside the structural driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+23.3%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-38.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-410%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-32.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
7.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-42.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
97.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-1.18$-1.42+16.9%
Q1 2026May 14, 2026$-0.97$-1.05+7.6%
Q4 2025Feb 26, 2026$-0.61$-1.24+50.8%
Q1 2025May 8, 2025$-0.90$-0.900.0%
Next earningsThu, Nov 12·consensus EPS $-0.87

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$3.0M—88.6%-753%$-1.18$-4.0M
Q1 FY26$19.6M—99.2%-88.0%$-0.97$-33.2M
Q4 FY25$859K—100%-5592%$-1.70$-20.1M
Q3 FY25$0———$0.00—

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$34.4M$20.1M – $48.3M-$4.58-$5.05 – -$4.103
FY27$4.0M$2.1M – $6.1M-$7.10-$7.14 – -$7.053
FY28$4.0M$2.3M – $5.6M-$6.53-$6.76 – -$6.312
FY29$1.6B$940.9M – $2.3B-$5.27-$8.04 – -$2.431
FY30$18.6M$10.9M – $26.1M-$4.98-$7.60 – -$2.291

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-30.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 15.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.375-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 8 other (8 inkinds) in window

See when $RNA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 13 other (7 13Gs · 2 10-Qs · 2 earnings 8-Ks · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)prnewswire.com·4d agoAvidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?defenseworld.net·16d agoAtrium Therapeutics to Participate in Upcoming Investor Conferencesprnewswire.com·23d agoAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com·36d agoAtrium Therapeutics Reports Second Quarter 2026 Financial Resultsprnewswire.com·43d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $RNA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport